{
    "clinical_study": {
        "@rank": "6704", 
        "arm_group": [
            {
                "arm_group_label": "Encapsulated vortioxetine IR tablet, 20 mg", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose"
            }, 
            {
                "arm_group_label": "Vortioxetine MR capsule 20 mg (pH 5.5)", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose"
            }, 
            {
                "arm_group_label": "Vortioxetine MR capsule 20 mg (pH 6.0)", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose"
            }, 
            {
                "arm_group_label": "Vortioxetine MR capsule 20 mg (pH 7.0)", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the gastro-intestinal tolerability (nausea,\n      vomiting, diarrhoea, abdominal discomfort, and abdominal pain) of vortioxetine following\n      single oral doses of three modified-release (MR) capsules with differently coated multiple\n      particles compared to one immediate-release (IR) tablet."
        }, 
        "brief_title": "Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women", 
        "condition": "Healthy Women", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy women \u226518 and \u226445 years of age with a body mass index (BMI) of >18.5 and\n             <30.0 kg/m2.\n\n          -  Women will be of child-bearing potential with a confirmed non-pregnant and\n             non-lactating status.\n\n        Other protocol-defined Inclusion and Exclusion Criteria may apply."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112903", 
            "org_study_id": "15947A", 
            "secondary_id": "2014-000121-20"
        }, 
        "intervention": [
            {
                "arm_group_label": "Encapsulated vortioxetine IR tablet, 20 mg", 
                "intervention_name": "Encapsulated vortioxetine IR tablet, 20 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vortioxetine MR capsule 20 mg (pH 5.5)", 
                "intervention_name": "Vortioxetine MR capsule 20 mg (pH 5.5)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vortioxetine MR capsule 20 mg (pH 6.0)", 
                "intervention_name": "Vortioxetine MR capsule 20 mg (pH 6.0)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vortioxetine MR capsule 20 mg (pH 7.0)", 
                "intervention_name": "Vortioxetine MR capsule 20 mg (pH 7.0)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "NW10 7EW"
                }, 
                "name": "GB801"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "4", 
        "official_title": "Interventional, Randomised, Double-blind 4-way Crossover Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women", 
        "overall_contact": {
            "email": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S"
        }, 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Gastro-intestinal tolerability (nausea) measured with 11-point Numerical Rating Scale", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 hours post-dose in each treatment period"
            }, 
            {
                "measure": "Gastro-intestinal tolerability (abdominal pain) measured with 11-point Numerical Rating Scale", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 hours post-dose in each treatment period"
            }, 
            {
                "measure": "Gastro-intestinal tolerability (abdominal discomfort) measured with 11-point Numerical Rating Scale", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 hours post-dose in each treatment period"
            }, 
            {
                "measure": "Frequency, severity and duration of reported gastro-intestinal tolerability (nausea, vomiting, diarrhoea, abdominal discomfort and abdominal pain)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 72 hours post-dose in each treatment period"
            }, 
            {
                "measure": "Area under the vortioxetine plasma concentration-time curve from zero to 72 hours post-dose (AUC0-72h)", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 hours postdose"
            }, 
            {
                "measure": "Maximum observed concentration (Cmax) of vortioxetine", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 hours postdose"
            }, 
            {
                "measure": "Nominal time corresponding to the occurrence of Cmax (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 hours postdose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112903"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}